The OPTIMIST-A trial: evaluation of minimally-invasive surfactant therapy in preterm infants 25–28 weeks gestation

BMC Pediatrics

Peter G Davis³  Roger F Soll²  Francesca Orsini⁴  John B Carlin¹  Antonio G De Paoli⁶  Camille Omar F Kamlin³  Peter A Dargaville⁵ 

[1] Department of Paediatrics, University of Melbourne, Melbourne, Australia;Department of Neonatology, Fletcher Allen Health Care; University of Vermont, Burlington, Vermont, USA;Murdoch Childrens Research Institute, Melbourne, Australia;Clinical Epidemiology and Biostatistics Unit, Murdoch Childrens Research Institute, Melbourne, Australia;Menzies Research Institute Tasmania, Hobart, Australia;Department of Paediatrics, Royal Hobart Hospital and University of Tasmania, Liverpool Street, Hobart TAS 7000, Australia

关键词: Bronchopulmonary dysplasia;    Pulmonary surfactants;    Continuous positive airway pressure;    Respiratory distress syndrome;    Preterm;    Infant;   

Others  :  1137299
DOI  :  10.1186/1471-2431-14-213

 received in 2014-07-04, accepted in 2014-08-12,  发布年份 2014

【 摘 要 】

Background

It is now recognized that preterm infants ≤28 weeks gestation can be effectively supported from the outset with nasal continuous positive airway pressure. However, this form of respiratory therapy may fail to adequately support those infants with significant surfactant deficiency, with the result that intubation and delayed surfactant therapy are then required. Infants following this path are known to have a higher risk of adverse outcomes, including death, bronchopulmonary dysplasia and other morbidities. In an effort to circumvent this problem, techniques of minimally-invasive surfactant therapy have been developed, in which exogenous surfactant is administered to a spontaneously breathing infant who can then remain on continuous positive airway pressure. A method of surfactant delivery using a semi-rigid surfactant instillation catheter briefly passed into the trachea (the “Hobart method”) has been shown to be feasible and potentially effective, and now requires evaluation in a randomised controlled trial.

Methods/design

This is a multicentre, randomised, masked, controlled trial in preterm infants 25–28 weeks gestation. Infants are eligible if managed on continuous positive airway pressure without prior intubation, and requiring FiO₂ ≥ 0.30 at an age ≤6 hours. Randomisation will be to receive exogenous surfactant (200 mg/kg poractant alfa) via the Hobart method, or sham treatment. Infants in both groups will thereafter remain on continuous positive airway pressure unless intubation criteria are reached (FiO₂ ≥ 0.45, unremitting apnoea or persistent acidosis). Primary outcome is the composite of death or physiological bronchopulmonary dysplasia, with secondary outcomes including incidence of death; major neonatal morbidities; durations of all modes of respiratory support and hospitalisation; safety of the Hobart method; and outcome at 2 years. A total of 606 infants will be enrolled. The trial will be conducted in >30 centres worldwide, and is expected to be completed by end-2017.

Discussion

Minimally-invasive surfactant therapy has the potential to ease the burden of respiratory morbidity in preterm infants. The trial will provide definitive evidence on the effectiveness of this approach in the care of preterm infants born at 25–28 weeks gestation.

Trial registration

Australia and New Zealand Clinical Trial Registry: ACTRN12611000916943; ClinicalTrials.gov: NCT02140580.

【 授权许可】

   
2014 Dargaville et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Suresh GK, Soll RF: Overview of surfactant replacement trials. J Perinatol 2005, 25(Suppl 2):S40-S44.
• [2]Lee K, Khoshnood B, Wall SN, Chang Y, Hsieh HL, Singh JK: Trend in mortality from respiratory distress syndrome in the United States, 1970–1995. J Pediatr 1999, 134:434-440.
• [3]Bohlin K, Jonsson B, Gustafsson AS, Blennow M: Continuous positive airway pressure and surfactant. Neonatology 2008, 93:309-315.
• [4]Morley CJ, Davis PG: Continuous positive airway pressure: scientific and clinical rationale. Curr Opin Pediatr 2008, 20:119-124.
• [5]Aly H, Massaro AN, Patel K, El Mohandes AA: Is it safer to intubate premature infants in the delivery room? Pediatrics 2005, 115:1660-1665.
• [6]Ammari A, Suri M, Milisavljevic V, Sahni R, Bateman D, Sanocka U, Ruzal-Shapiro C, Wung JT, Polin RA: Variables associated with the early failure of nasal CPAP in very low birth weight infants. J Pediatr 2005, 147:341-347.
• [7]Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet JM, Carlin JB: Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008, 358:700-708.
• [8]Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, Das A, Poole WK, Donovan EF, Newman NS, Ambalavanan N, Frantz ID III, Buchter S, Sanchez PJ, Kennedy KA, Laroia N, Poindexter BB, Cotten CM, Van Meurs KP, Duara S, Narendran V, Sood BG, O'Shea TM, Bell EF, Bhandari V, Watterberg KL, Higgins RD: Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010, 362:1970-1979.
• [9]Dunn MS, Kaempf J, de Klerk A, de Klerk R, Reilly M, Howard D, Ferrelli K, O’Conor J, Soll RF, Vermont Oxford Network DRM Study Group: Randomized trial comparing 3 approaches to the initial respiratory management of preterm neonates. Pediatrics 2011, 128:e1069-e1076.
• [10]Dargaville PA, Aiyappan A, De Paoli AG, Dalton RG, Kuschel CA, Kamlin CO, Orsini F, Carlin JB, Davis PG: Continuous positive airway pressure failure in preterm infants: incidence, predictors and consequences. Neonatology 2013, 104:8-14.
• [11]OSIRIS Collaborative Group: Early versus delayed neonatal administration of a synthetic surfactant–the judgment of OSIRIS. Lancet 1992, 340:1363-1369.
• [12]Yost CC, Soll RF: Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2000, 2:CD001456.
• [13]Geary CA, Fonseca RA, Caskey MA, Malloy MH: Improved growth and decreased morbidities in <1000 g neonates after early management changes. J Perinatol 2008, 28:347-353.
• [14]Bohlin K, Gudmundsdottir T, Katz-Salamon M, Jonsson B, Blennow M: Implementation of surfactant treatment during continuous positive airway pressure. J Perinatol 2007, 27:422-427.
• [15]Cherif A, Hachani C, Khrouf N: Risk factors of the failure of surfactant treatment by transient intubation during nasal continuous positive airway pressure in preterm infants. Am J Perinatol 2008, 25:647-652.
• [16]Verder H, Robertson B, Greisen G, Ebbesen F, Albertsen P, Lundstrom K, Jacobsen T: Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome. Danish-Swedish Multicenter Study Group. N Engl J Med 1994, 331:1051-1055.
• [17]Verder H, Albertsen P, Ebbesen F, Greisen G, Robertson B, Bertelsen A, Agertoft L, Djernes B, Nathan E, Reinholdt J: Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks’ gestation. Pediatrics 1999, 103:E24.
• [18]Escobedo MB, Gunkel JH, Kennedy KA, Shattuck KE, Sanchez PJ, Seidner S, Hensley G, Cochran CK, Moya F, Morris B, Denson S, Stribley R, Naqvi M, Lasky RE: Early surfactant for neonates with mild to moderate respiratory distress syndrome: a multicenter, randomized trial. J Pediatr 2004, 144:804-808.
• [19]Reininger A, Khalak R, Kendig JW, Ryan RM, Stevens TP, Reubens L, D'Angio CT: Surfactant administration by transient intubation in infants 29 to 35 weeks’ gestation with respiratory distress syndrome decreases the likelihood of later mechanical ventilation: a randomized controlled trial. J Perinatol 2005, 25:703-708.
• [20]Rojas MA, Lozano JM, Rojas MX, Laughon M, Bose CL, Rondon MA, Charry L, Bastidas JA, Perez LA, Rojas C, Ovalle O, Celis LA, Garcia-Harker J, Jaramillo ML: Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: a randomized, controlled trial. Pediatrics 2009, 123:137-142.
• [21]Sandri F, Plavka R, Ancora G, Simeoni U, Stranak Z, Martinelli S, Mosca F, Nona J, Thomson M, Verder H, Fabbri L, Halliday H: Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. Pediatrics 2010, 125:e1402-e1409.
• [22]Verder H, Bohlin K, Kamper J, Lindwall R, Jonsson B: Nasal CPAP and surfactant for treatment of respiratory distress syndrome and prevention of bronchopulmonary dysplasia. Acta Paediatr 2009, 98:1400-1408.
• [23]O’Donnell CP, Kamlin CO, Davis PG, Morley CJ: Endotracheal intubation attempts during neonatal resuscitation: success rates, duration, and adverse effects. Pediatrics 2006, 117:e16-e21.
• [24]Simon L, Trifa M, Mokhtari M, Hamza J, Treluyer JM: Premedication for tracheal intubation: a prospective survey in 75 neonatal and pediatric intensive care units. Crit Care Med 2004, 32:565-568.
• [25]Bohlin K, Bouhafs RK, Jarstrand C, Curstedt T, Blennow M, Robertson B: Spontaneous breathing or mechanical ventilation alters lung compliance and tissue association of exogenous surfactant in preterm newborn rabbits. Pediatr Res 2005, 57:624-630.
• [26]Kattwinkel J, Robinson M, Bloom BT, Delmore P, Ferguson JE: Technique for intrapartum administration of surfactant without requirement for an endotracheal tube. J Perinatol 2004, 24:360-365.
• [27]Trevisanuto D, Grazzina N, Ferrarese P, Micaglio M, Verghese C, Zanardo V: Laryngeal mask airway used as a delivery conduit for the administration of surfactant to preterm infants with respiratory distress syndrome. Biol Neonate 2005, 87:217-220.
• [28]Finer NN, Merritt TA, Bernstein G, Job L, Mazela J, Segal R: An open label, pilot study of Aerosurf(R) combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulm Drug Deliv 2010, 23:303-309.
• [29]Verder H, Agertoft L, Albertsen P, Christensen NC, Curstedt T, Ebbesen F, Greisen G, Hobolth N, Holm V, Jacobsen T: [Surfactant treatment of newborn infants with respiratory distress syndrome primarily treated with nasal continuous positive air pressure. A pilot study]. [Danish]. Ugeskr Laeger 1992, 154:2136-2139.
• [30]Kribs A, Pillekamp F, Hunseler C, Vierzig A, Roth B: Early administration of surfactant in spontaneous breathing with nCPAP: feasibility and outcome in extremely premature infants (postmenstrual age
• [31]Kribs A: Early administration of surfactant in spontaneous breathing with nCPAP through a thin endotracheal catheter–an option in the treatment of RDS in ELBW infants? J Perinatol 2009, 29:256.
• [32]Kribs A, Hartel C, Kattner E, Vochem M, Kuster H, Moller J, Muller D, Segerer H, Wieg C, Gebauer C, Nikischin W, Wense A, Herting E, Roth B, Gopel W: Surfactant without intubation in preterm infants with respiratory distress: first multi-center data. Klin Padiatr 2010, 222:13-17.
• [33]Göpel W, Kribs A, Ziegler A, Laux R, Hoehn T, Wieg C, Siegel J, Avenarius S, von der WA, Vochem M, Groneck P, Weller U, Moller J, Hartel C, Haller S, Roth B, Herting E: Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet 2011, 378:1627-1634.
• [34]Kanmaz HG, Erdeve O, Canpolat FE, Mutlu B, Dilmen U: Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics 2013, 131:e502-e509.
• [35]Dargaville PA, Aiyappan A, Cornelius A, Williams C, De Paoli AG: Preliminary evaluation of a new technique of minimally invasive surfactant therapy. Arch Dis Child Fetal Neonatal Ed 2011, 96:F243-F248.
• [36]Dargaville PA, Aiyappan A, De Paoli AG, Kuschel CA, Kamlin CO, Carlin JB, Davis PG: Minimally-invasive surfactant therapy in preterm infants on continuous positive airway pressure. Arch Dis Child Fetal Neonatal Ed 2013, 98:F122-F126.
• [37]Fiori HH, Fritscher CC, Fiori RM: Selective surfactant prophylaxis in preterm infants born at < or =31 weeks’ gestation using the stable microbubble test in gastric aspirates. J Perinat Med 2006, 34:66-70.
• [38]Osborn DA, Lockley C, Jeffery HE, Lloyd J, Lazarus R: Interobserver reliability of the click test: a rapid bedside test to determine surfactant function. J Paediatr Child Health 1998, 34:544-547.
• [39]De Jaegere AP, van der Lee JH, Cante C, van Kaam AH: Early prediction of nasal continuous positive airway pressure failure in preterm infants less than 30 weeks gestation. Acta Paediatr 2011, 101:374-379.
• [40]Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K: A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004, 21:109-119.
• [41]Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W: Caffeine therapy for apnea of prematurity. N Engl J Med 2006, 354:2112-2121.
• [42]Walsh MC, Yao Q, Gettner P, Hale E, Collins M, Hensman A, Everette R, Peters N, Miller N, Muran G, Auten K, Newman N, Rowan G, Grisby C, Arnell K, Miller L, Ball B, McDavid G: Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics 2004, 114:1305-1311.
• [43]Benaron DA, Benitz WE: Maximizing the stability of oxygen delivered via nasal cannula. Arch Pediatr Adolesc Med 1994, 148:294-300.
• [44]Dargaville PA, Keszler M: Setting the ventilator in the NICU. In Neonatal and Paediatric Mechanical Ventilation. Edited by Rimensberger PC. Berlin Heidelberg: Springer; 2014.
• [45]Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM: Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988, 82:527-532.
• [46]Papile LA, Burstein J, Burstein R, Koffler H: Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978, 92:529-534.
• [47]Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF: Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA 2003, 289:1124-1129.
• [48]Walsh MC, Kliegman RM, Fanaroff AA: Necrotizing enterocolitis: a practitioner’s perspective. Pediatr Rev 1988, 9:219-226.
• [49]Campbell MJ, Julious SA, Altman DG: Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ 1995, 311:1145-1148.
• [50]Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, Elbourne DR, McLeer SK, Parmar MK, Pocock SJ, Spiegelhalter DJ, Sydes MR, Walker AE, Wallace SA: Issues in data monitoring and interim analysis of trials. Health Technol Assess 2005, 9:1-238.